EONE-DIAGNOMICS Genome Center announced the release of a liquid biopsy screening service. The service is a non-invasive liquid biopsy technology which has drawn attention as the most promising advanced diagnosis technology with the development of NGS technology. The liquid biopsy technology is a technology that Grail, Illumina Inc. spin-out, and others have raised about KRW 1.8 billion funds to develop it. It is useful for preventing any recurrence in patients with cancer and early detection of cancer. The liquid biopsy screening technology is known as the most advanced liquid biopsy technology that is able to early detect various cancers with a simple blood test from people without any signs or symptoms, and it is only capable through comprehensive analysis of samples, various biomarkers measurements and precise algorithms. The liquid biopsy screening service commercialized this time would be provided to the global market through CLIA certification in the United States. Also, it would predict risk of cancers statistically and detect even microscopic factors leading to cancers, analyzing both inherent risk of cancers and acquired biomarkers simultaneously.